Published in J Antimicrob Chemother on January 30, 2006
Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev (2007) 15.82
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Updated functional classification of beta-lactamases. Antimicrob Agents Chemother (2009) 7.16
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev (2012) 5.65
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 2.30
Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing Gram-negative bacilli. J Clin Microbiol (2013) 2.09
Multidrug resistant acinetobacter. J Glob Infect Dis (2010) 1.94
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 1.72
OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak. Antimicrob Agents Chemother (2010) 1.67
Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci U S A (2007) 1.63
Emergence of PER-2 and VEB-1a in Acinetobacter baumannii Strains in the Americas. Antimicrob Agents Chemother (2006) 1.57
Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care (2010) 1.57
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 1.38
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother (2009) 1.37
Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J Am Chem Soc (2008) 1.32
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. Antimicrob Agents Chemother (2008) 1.30
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother (2007) 1.27
Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem. J Mol Biol (2011) 1.22
Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2013) 1.21
Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China. J Clin Microbiol (2007) 1.17
Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed Res Int (2014) 1.16
Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther (2008) 1.09
Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem (2010) 1.09
Exploring the evolutionary dynamics of plasmids: the Acinetobacter pan-plasmidome. BMC Evol Biol (2010) 1.08
Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii. Chem Biol (2013) 1.08
Structures of the class D Carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam. Antimicrob Agents Chemother (2013) 1.07
OXA-198, an acquired carbapenem-hydrolyzing class D beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (2011) 1.07
Inhibition of OXA-1 beta-lactamase by penems. Antimicrob Agents Chemother (2008) 1.04
Whole genome sequence analysis of the first Australian OXA-48-producing outbreak-associated Klebsiella pneumoniae isolates: the resistome and in vivo evolution. PLoS One (2013) 1.04
Class D β-lactamases: are they all carbapenemases? Antimicrob Agents Chemother (2014) 0.96
Survey on antimicrobial resistance patterns in Vibrio vulnificus and Vibrio cholerae non-O1/non-O139 in Germany reveals carbapenemase-producing Vibrio cholerae in coastal waters. Front Microbiol (2015) 0.95
First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy. Antimicrob Agents Chemother (2006) 0.94
Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar. Ann Clin Microbiol Antimicrob (2010) 0.94
Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases. Antimicrob Agents Chemother (2014) 0.93
Penicillin sulfone inhibitors of class D beta-lactamases. Antimicrob Agents Chemother (2010) 0.93
Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. Pak J Med Sci (2013) 0.91
Hydrolytic mechanism of OXA-58 enzyme, a carbapenem-hydrolyzing class D β-lactamase from Acinetobacter baumannii. J Biol Chem (2011) 0.90
Double- and multi-carbapenemase-producers: the excessively armored bacilli of the current decade. Eur J Clin Microbiol Infect Dis (2015) 0.90
Structural Basis for Different Substrate Profiles of Two Closely Related Class D β-Lactamases and Their Inhibition by Halogens. Biochemistry (2015) 0.90
The Class D beta-lactamase family: residues governing the maintenance and diversity of function. Protein Eng Des Sel (2011) 0.90
Crystal structure of carbapenemase OXA-58 from Acinetobacter baumannii. Antimicrob Agents Chemother (2014) 0.88
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases (2014) 0.88
Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance. Int J Mol Sci (2015) 0.86
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. Antimicrob Agents Chemother (2009) 0.85
Site-saturation mutagenesis of position V117 in OXA-1 β-lactamase: effect of side chain polarity on enzyme carboxylation and substrate turnover. Biochemistry (2012) 0.85
Dissemination of blaOXA-23 in Acinetobacter spp. in China: main roles of conjugative plasmid pAZJ221 and transposon Tn2009. Antimicrob Agents Chemother (2015) 0.85
Can we use imipenem and meropenem Vitek 2 MICs for detection of suspected KPC and other-carbapenemase producers among species of Enterobacteriaceae? J Clin Microbiol (2010) 0.84
Susceptibilities of common bacterial isolates from oman to old and new antibiotics. Oman Med J (2008) 0.83
First report of carbapenem-resistant Acinetobacter nosocomialis isolates harboring ISAba1-blaOXA-23 genes in Latin America. J Clin Microbiol (2013) 0.83
Expression of OXA-type and SFO-1 β-lactamases induces changes in peptidoglycan composition and affects bacterial fitness. Antimicrob Agents Chemother (2012) 0.83
Dissemination of carbapenemases producing Gram negative bacteria in the Middle East. Iran J Microbiol (2015) 0.83
Characterization of Carbapenemases in Extensively Drug Resistance Acinetobacter baumannii in a Burn Care Center in Iran. Int J Mol Cell Med (2015) 0.82
Performance of the CLSI Carba NP and the Rosco Carb Screen Assays Using North American Carbapenemase-Producing Enterobacteriaceae and Pseudomonas aeruginosa Isolates. J Clin Microbiol (2015) 0.82
Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis (2016) 0.82
New Delhi metallo-β-lactamase and OXA-48 carbapenemases in Gram-negative bacilli isolates in Libya. Libyan J Med (2015) 0.82
Low genetic diversity of the intrinsic OXA-51-like class D carbapenemases among Acinetobacter baumannii clinical isolates in Greece. Epidemiol Infect (2006) 0.81
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. Antimicrob Agents Chemother (2008) 0.81
Molecular and epidemiological characterization of carbapenem-resistant Acinetobacter baumannii in non-tertiary Korean hospitals. Yonsei Med J (2013) 0.81
Phytochemistry and Preliminary Assessment of the Antibacterial Activity of Chloroform Extract of Amburana cearensis (Allemão) A.C. Sm. against Klebsiella pneumoniae Carbapenemase-Producing Strains. Evid Based Complement Alternat Med (2014) 0.79
Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front Microbiol (2015) 0.78
Distinct roles of major peptidoglycan recycling enzymes in β-Lactamase production in Shewanella oneidensis. Antimicrob Agents Chemother (2014) 0.78
In vivo protein interaction network analysis reveals porin-localized antibiotic inactivation in Acinetobacter baumannii strain AB5075. Nat Commun (2016) 0.78
Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. Proc Natl Acad Sci U S A (2017) 0.78
Osteomyelitis due to multiple carbapenemase-producing Gram-negative bacteria: The first case report of a GES-13-producing Pseudomonas aeruginosa isolate in Canada. Can J Infect Dis Med Microbiol (2014) 0.78
Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist (2014) 0.77
PBP1a/LpoA but not PBP1b/LpoB are involved in regulation of the major β-lactamase gene blaA in Shewanella oneidensis. Antimicrob Agents Chemother (2015) 0.77
Acquired Class D β-Lactamases. Antibiotics (Basel) (2014) 0.77
Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia. Ann Clin Microbiol Antimicrob (2015) 0.77
Oligonucleotide microarray for the identification of carbapenemase genes of molecular classes a, B, and d. Acta Naturae (2010) 0.76
Class D β-lactamases do exist in Gram-positive bacteria. Nat Chem Biol (2015) 0.76
Prevalence of Class D Carbapenemases among Extended-Spectrum β-Lactamases Producing Escherichia coli Isolates from Educational Hospitals in Shahrekord. J Clin Diagn Res (2016) 0.75
Expansion of highly stable bla OXA-10 β-lactamase family within diverse host range among nosocomial isolates of Gram-negative bacilli within a tertiary referral hospital of Northeast India. BMC Res Notes (2017) 0.75
Resistance mechanisms. Ann Transl Med (2016) 0.75
Prevalence of carbapenemases among high-level aminoglycoside-resistant Acinetobacter baumannii isolates in a university hospital in China. Exp Ther Med (2016) 0.75
A genome-wide association study identifies a horizontally transferred bacterial surface adhesin gene associated with antimicrobial resistant strains. Sci Rep (2016) 0.75
Purification and characterization of a new β-lactamase OXA-205 from Pseudomonas aeruginosa. Ann Clin Microbiol Antimicrob (2015) 0.75
Disk Carbapenemase Test for the Rapid Detection of KPC-, NDM-, and Other Metallo-β-Lactamase-Producing Gram-Negative Bacilli. Ann Lab Med (2016) 0.75
Complete genome of the multidrug-resistant Acinetobacter baumannii strain KBN10P02143 isolated from Korea. Mem Inst Oswaldo Cruz (2016) 0.75
Characterization of Novel Integrons, In1085 and In1086, and the Surrounding Genes in Plasmids from Enterobacteriaceae, and the Role for attCaadA16 Structural Features during attI1 × attC Integration. Front Microbiol (2017) 0.75
The role of conserved surface hydrophobic residues in the carbapenemase activity of the class D β-lactamases. Acta Crystallogr D Struct Biol (2017) 0.75
Molecular Characterization of Klebsiella pneumoniae Clinical Isolates with Elevated Resistance to Carbapenems. Open Microbiol J (2017) 0.75
Activity of the β-Lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii. Antimicrob Agents Chemother (2017) 0.75
Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78
Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology (2002) 3.37
Evolutionary dynamics of bacteria in a human host environment. Proc Natl Acad Sci U S A (2011) 2.75
Class A carbapenemases. J Antimicrob Chemother (2007) 2.72
Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen (2008) 2.58
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol (2009) 2.53
Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol (2012) 2.50
Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology (2005) 2.24
Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology (2009) 2.06
Distribution, organization, and ecology of bacteria in chronic wounds. J Clin Microbiol (2008) 2.05
Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob Agents Chemother (2004) 1.99
Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother (2005) 1.94
Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology (2007) 1.88
Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother (2002) 1.85
Applying insights from biofilm biology to drug development - can a new approach be developed? Nat Rev Drug Discov (2013) 1.82
Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J Antimicrob Chemother (2012) 1.81
Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun (2007) 1.81
The in vivo biofilm. Trends Microbiol (2013) 1.79
Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother (2007) 1.71
Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology (2005) 1.70
Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun (2005) 1.69
Biofilms in chronic infections - a matter of opportunity - monospecies biofilms in multispecies infections. FEMS Immunol Med Microbiol (2010) 1.68
Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.67
Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J (2011) 1.59
Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol (2005) 1.55
Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol (2010) 1.54
Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol (2003) 1.50
Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and PoxB beta-lactamases, proteases, quorum sensing, and other virulence factors. Antimicrob Agents Chemother (2005) 1.48
In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol (2007) 1.46
Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology (2009) 1.45
Bacterial biofilm formation and treatment in soft tissue fillers. Pathog Dis (2014) 1.44
The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication. Microbiology (2005) 1.43
Towards diagnostic guidelines for biofilm-associated infections. FEMS Immunol Med Microbiol (2012) 1.43
Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS One (2010) 1.42
[Antibiotic treatment in four departments of a university hospital. A descriptive period prevalence study]. Ugeskr Laeger (2005) 1.40
[Current microbiologic strategy in endocarditis]. Ugeskr Laeger (2003) 1.38
[Fatal outcome of pneumococcal pneumonia--a consequence of macrolide resistance?]. Ugeskr Laeger (2004) 1.38
[Calculated consequences of the Danish treatment of Staphylococcus aureus bacteremia and meningitis]. Ugeskr Laeger (2003) 1.37
Alginate production affects Pseudomonas aeruginosa biofilm development and architecture, but is not essential for biofilm formation. J Med Microbiol (2004) 1.34
PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother (2011) 1.33
Silver against Pseudomonas aeruginosa biofilms. APMIS (2007) 1.33
Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros (2008) 1.32
PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother (2011) 1.32
Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. PLoS One (2011) 1.31
Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases. Can J Microbiol (2004) 1.30
Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros (2006) 1.30
Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med (2013) 1.28
Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. PLoS One (2013) 1.25
Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob Agents Chemother (2012) 1.23
Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis (2010) 1.21
Plasmid-borne AmpC beta-lactamases. Can J Microbiol (2002) 1.21
Lipocalin 2 is protective against E. coli pneumonia. Respir Res (2010) 1.19
Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2013) 1.17
Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2004) 1.17
Environmental heterogeneity drives within-host diversification and evolution of Pseudomonas aeruginosa. MBio (2014) 1.16
Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol (2003) 1.14
Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr (2006) 1.13
Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol (2004) 1.13
Comparative genomic analysis of rapid evolution of an extreme-drug-resistant Acinetobacter baumannii clone. Genome Biol Evol (2013) 1.12
Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS (2009) 1.12
Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2011) 1.10
Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. Microbiology (2007) 1.09
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros (2005) 1.09
In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother (2012) 1.06
Interference of Pseudomonas aeruginosa signalling and biofilm formation for infection control. Expert Rev Mol Med (2010) 1.05
Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response. J Cyst Fibros (2012) 1.04
Clearance of Pseudomonas aeruginosa foreign-body biofilm infections through reduction of the cyclic Di-GMP level in the bacteria. Infect Immun (2013) 1.04
Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax (2010) 1.03
Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. Microbiology (2008) 1.02
Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms. Orthop Rev (Pavia) (2013) 1.02
Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa. Appl Environ Microbiol (2012) 1.01
Polysaccharides serve as scaffold of biofilms formed by mucoid Pseudomonas aeruginosa. FEMS Immunol Med Microbiol (2012) 1.00
The implication of Pseudomonas aeruginosa biofilms in infections. Inflamm Allergy Drug Targets (2011) 0.99
P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs. J Cyst Fibros (2013) 0.99
Combating biofilms. FEMS Immunol Med Microbiol (2012) 0.98
Biological Trojan horse: Antigen 43 provides specific bacterial uptake and survival in human neutrophils. Infect Immun (2006) 0.97
Interactions between polymorphonuclear leukocytes and Pseudomonas aeruginosa biofilms on silicone implants in vivo. Infect Immun (2012) 0.97
Pattern differentiation in co-culture biofilms formed by Staphylococcus aureus and Pseudomonas aeruginosa. FEMS Immunol Med Microbiol (2011) 0.97
Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis. PLoS One (2012) 0.97
Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. APMIS (2011) 0.96
Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol (2009) 0.95
Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunol Med Microbiol (2012) 0.95
High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2012) 0.95
True microbiota involved in chronic lung infection of cystic fibrosis patients found by culturing and 16S rRNA gene analysis. J Clin Microbiol (2011) 0.94
Pseudomonas aeruginosa biofilm aggravates skin inflammatory response in BALB/c mice in a novel chronic wound model. Wound Repair Regen (2013) 0.93
Bacterial adaptation during chronic infection revealed by independent component analysis of transcriptomic data. BMC Microbiol (2011) 0.93
Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS (2009) 0.93
Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study. J Cyst Fibros (2006) 0.92
Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems. Antimicrob Agents Chemother (2013) 0.92
Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine (2006) 0.92
Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics. Clin Microbiol Infect (1996) 0.92
Effects of ginseng on Pseudomonas aeruginosa motility and biofilm formation. FEMS Immunol Med Microbiol (2011) 0.91
Use of cultivation-dependent and -independent techniques to assess contamination of central venous catheters: a pilot study. BMC Clin Pathol (2008) 0.90
Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2012) 0.90
Decreased mucosal oxygen tension in the maxillary sinuses in patients with cystic fibrosis. J Cyst Fibros (2011) 0.90
Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros (2008) 0.90
Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.90
Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. J Antimicrob Chemother (2010) 0.89
Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros (2012) 0.87